No connection

Search Results

Healthcare Score 35 Neutral

Novo Nordisk's Wegovy Pill Gains Traction Among Needle-Averse Patients

Apr 07, 2026 11:00 UTC
NOVO-B.CO, ^GSPC, RXPH
Medium term

The launch of Novo Nordisk's oral Wegovy pill has drawn a new wave of patients into GLP-1 weight loss treatments, particularly those who previously avoided injections due to cost or fear of needles.

  • Over 600,000 prescriptions for Novo Nordisk's Wegovy pill have been written since its launch in early January.
  • The pill's entry price of $149 per month is among the lowest for GLP-1 therapies.
  • The drug is attracting patients who avoid injections due to cost or fear of needles, estimated to affect up to 25% of U.S. adults.
  • Eli Lilly's new GLP-1 pill, Foundayo, poses competition with fewer dietary restrictions.
  • Analysts expect Wegovy's overall portfolio sales to rise from $13.5 billion in 2026 to $18.9 billion in 2031, with the pill contributing $2.76 billion.

Novo Nordisk's new oral Wegovy pill has seen strong early adoption, with over 600,000 prescriptions written since its launch in early January. Patients like Jane Zuckerman, a 32-year-old data analyst in Washington, D.C., have reported initial weight loss success, with Zuckerman shedding 11 pounds in a month. The pill is attracting individuals who have long avoided GLP-1 treatments due to high out-of-pocket costs for injections or a fear of needles. Analysts note that the pill is expanding the obesity treatment market by drawing in new patients rather than converting existing injection users. The drug's entry price of $149 per month is considered one of the lowest for a GLP-1 therapy, making it an attractive option for cost-sensitive patients. However, Novo faces competition from Eli Lilly, which recently received U.S. approval for its own GLP-1 pill, Foundayo, which lacks dietary restrictions associated with Novo's product. Despite the pill's strong launch, Novo's stock has not seen a significant boost as the company works to regain market share from Lilly and demonstrate growth beyond its existing products.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile